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THE contributions made by the various eicosanoids, PAF,
the HETES and the lipoxins to the pathophysiology of
glomerulonephritis is reviewed. A case can be made for
clinical trials of PAF, leukotriene and thromboxane ant-
agonists. Combined thromboxane synthetase and throm-
boxane receptor antagonism would seem to be the more
efficacious approach for the various disease entities.
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Introduction
Glomerulonephritis is inflammation of the
glomerular filtering units of the kidneys, that is
caused either by deposition of immune complexes
following infections or by formation of an antibody
that interacts with the basement membranes of the
capillaries of the glomeruli. Such inflammation will
be accompanied by immediate deposition of platelet
aggregates in the capillaries and a rapid infiltration
with polymorphonuclear leucocytes (PMNs), and a
slower infiltration of monocytes and macrophages.
Thus filtration is impaired, so that the blood urea
rises, and leakage of protein through permable
capillaries results in a variable loss of protein in the
urine called proteinuria.
We are now in a position to define the several
roles of the phospholipid derived mediators, such
as the various eicosanoids, PAF, the HETES and
the lipoxins in glomerulonephritides. This has
entailed examining their actions on the intrinsic
cells of the glomeruli, like the capillary endothelial
cells, the central stalk mesangial cells and the
epithelial cells that lie on the urinary side of the
filtration surface, which is the glomerular basement
membrane (GBM). Their effects on the cells that
become lodged in or that infiltrate the glomeruli,
namely the platelets, PMNs and the monocyte-
macrophages must also be accounted for.
As with inflammation at any site, vascular
permeability that results in the leakage of protein
rich fluid into the extravascular space is mediated
by the combined action of vasodilator prostagland-
ins, that promote increased blood flow through
arterioles and capillaries, and the peptidoleuko-
trienes that cause postcapillary venular constric-
tion. Leukotriene D4 is a principal mediator,
2 and
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PAF
3 and the HETE molecules act synergistically,
since they cause contraction of vascular endothelial
cells,4,s and they will add to the effects of other
agents like histamine, bradykinin and the anaphyla-
toxins that arise during the activation of comple-
ment. Loss of negatively charged heparan sulphate
molecules from the walls of the glomerular
capillaries is an important accessory process which
means that albumin molecules are no longer
subjected to ’charge repulsion’ and so there is
leakage of albumin. Heparitinases produced by
platelets, and the lysosomal neutral proteinases of
white cells that include proteoglycanases, aid such
losses. At any rate involvement of platelets in the
various forms of glomerulonephritis,
6 and the
recruitment of PMNs followed soon by monocyte-
macrophages is an integral part of the process.
Involvement of these phagocytic cells in free radical
generating reactions is then accompanied by
formation of leukotrienes,
8 as does damage to cells
by complement mediated reactions. Table 1
emphasizes the various roles of the phospholipid
derived mediators in the complex pathophysiology
of glomerulonephritides that have been deduced
from animal experiments.
Survey of Table 1 reveals that the phospholipid
derivatives have vascular effects that account for
modulation of blood flow through the inflamed
glomeruli in nephritis and that all have some effect
on vascular permeability and hence proteinuria.
Additionally the mediators control the responses of
platelets, PMNs and infiltrating macrophages, and
they alter the responses of mesangial stalk cells and
thus modulate glomerular blood flow and filtration
of urine. The thromboxanes even determine
protein synthesis by the mesangial cells,
22 and the
formation of extracellular matrix proteins like
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Table 1. Pharmacological actions of phospholipid-derived mediators
Mediator Vascular effect Cellular action
PG 12 Vasodilatation
PG E1 Vasodilatation
PGE2 Vasodilatation, proteinuria9
PGF2 Vasoconstriction
TxA2 Vasoconstriction
Lowers GFR and plasma flow, 11
Causes proteinuria, 2
Salt and water retention.3
LTB4 Vascular permeability6
LTC4-D4
HETES
Lipoxins
PAF
Vascular permeability proteinuria2
Vascular permeability8
LXA4 vasodilator7’2 counteracts
leukotrienes.
LXB4 lowers the GFR2
Vascular permeability and proteinuria3
Loss of anionic charges.21
Inhibits platelet aggregation
Inhibits platelet aggregation
Causes platelet aggregation
Mesangial cell proliferation
Causes platelet aggregation,
Mesangial matrix formation,TM
Enhances T-cell responses.5
Chemotaxis for white cells,6
Activation of PMNs and macrophages.
Contraction of mesangial cells, so lowering the GFR. 17
5HETE--PAF synthesis8
12H ETE--chemotaxis8
15HETE--endothelial proliferation
15HETEinhibition of LTB4 synthesis.7
Reduce PMN reactivity9
Mesangial cell contraction and reduction of the G FR3
fibronectin that determine the onset of the fibrosis
that leads to glomerulosclerosis and ultimate
destruction.
Specific role of the mediators in
nephritides
Culture of whole glomeruli or isolated mesangial
cells
23 has been used to study biochemical
pharmacology. So it was shown that PGF2
1 will
act synergistically with growth factors to cause
mesangial cell proliferation, and studies have been
done on the interaction of cytokines and eicosa-
noids.24 In the study of the various animal models
of glomerulonephritis, one has to examine the eect
of pharmacological mediators on physiological
responses by using micropuncture studies,25’26 and
studies of the porosity of the glomerular capillary
walls to dextrans of defined size and charge. In
nephritides one will expect an increase in renal
cortical plasma flow and yet a reduction of the
glomerular filtration rate (GFR), and a marked
reduction of the glomerular capillary ultrafiltration
coeflqcient, Kf.
26
In all types of nephritis there is complement
activation and increased leukotriene synthesis, and
hence vascular permeability and a fall of GFR and
an infiltration of PMNs. There is an important role
for thromboxane A2 in mediating the increase of
renal vascular resistance during this early phase. 2v’28
However soon this will be counteracted by the
production of vasodilators like nitric oxide
originating from endothelial cells,29’3 increased
production of PGE2,
2 and the formation of lipoxin
A4 that causes arteriolar dilatation.1 So then there
will be increased blood flow and yet low GFR and
K.
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There is an early burst of glomerular synthesis
of leukotrienes, following which they are sup-
pressed. 7’8 Early production of PAF-acether con-
tributes to the formation of leukotrienes.2 LTB4
accounts for the attraction of PMNs into the
glomeruli
1 along with cytokines like interleukin-8.
LTB4 accounts for attraction of monocyte-
macrophages along with chemokines like monocyte
chemoattractant protein, MCP-1. Leukotrienes
C4-D4 cause deterioration of glomerular function
and in the ultrafiltration coeflqcient, Kf, as proven
by the improvement that is achieved with a
leukotriene D4 antagonist.
33 Indeed it has been
known for a long time that nephritis is ameliorated
by rendering animals neutropenic.
There is also a free radical catalysed lipid
peroxidation product 8 epi-PGF2 (an eight
isoprostane), which turns out to cause mesangial
cell contraction and reduction of glomerular blood
flow and filtration.4 This mediator was discovered
whilst pursuing the fact that short term cholesterol
feeding to rats causes renal vasoconstriction that is
overcome by a thromboxane receptor antagonist.
3s
At any rate the appearance of macrophages
within the glomeruli means that there is now local
production of 15HETE. 15HETE abolishes the
chemotactic response ofPMNs (certainly in the rat).
It is converted to lipoxin A4"’ which is antagonistic
to LTB4.’v Hence, according to Badr, the GFR
is now improved. Even more significantly 15HETE
synthesis is thought to account for the dis-
appearance of PMNs from the glomeruli. Its
production increases progressively over days and
even weeks, since there are now many local
macrophages. Unfortunately it is known that their
presence portends glomerulo-fibrosis.Glomerulonephritis
All this means that in the later stage of nephritis
poor glomerular function is more likely to be
mediated by thromboxane A2 .7’26 Thromboxane
production also accounts for proteinuria.
36 PAF is
yet another factor,
39 but we should note that many
actions of PAF are probably mediated via
thromboxane.4 Selective antagonism of thrombox-
ane will certainly improve the GFR in all the models
of nephritis,
41-43 and usually proteinuria is lessened.
Much interest is now centred on the fact that
thromboxanes that are released during glomerular
injury lead to proliferation of mesangial cells,
41 and
they promote formation of extracellular matrix
proteins. 14’22’45 They also will be produced by
macrophages. Concurrent lipid peroxidation leads
to collagen formation. 46’47 Now it is recognized that
the cytokine transforming growth factor beta leads
to collagen formation and glomerulosclerosis, since
TGFfl also inhibits local metalloproteinases.
48 The
inter-relationships between these factors have not
been explored as yet. Often mesangial cells produce
type I collagen and epithelial cells produce type IV
collagen.
There is ample evidence that renal perfusion is
maintained during glomerulonephritis by the
vasodilator action of prostaglandins,
7 albeit they
also facilitate leakage of protein
27-28 through the
glomeruli. It is salutary to reflect that production
of prostaglandins PGE2, PGF2 and PGI2 is
increased as a consequence of complement mediated
damage to glomerular cells,
49 as a result of local
production of oxygen radicals,
5 and in response to
the proinflammatory cytokines like IL-1 and
TNF0,
51 and that their ultimate role is likely to be
cytoprotective ’.
The question will arise as to whether all of these
proinflammatory mediators are involved in the
same way in each different histological form of
nephritis. Generally this discussion applies to all
forms of proliferative nephritis. In these there is
infiltration of PMNs followed by monocyte-
macrophages, and there is throughout an over-
riding role for the thromboxanes,
41-43 for throm-
boxane antagonists lessen the cellular proliferation
and extracellular matrix deposition that leads to
glomerulosclerosis and the proteinuria.
Similar mediators are certainly involved in
’membranous nephropathy’ in which the capillary
loop basement membranes appear thickened. This
is not surprizing because involvement of the
underlying epithelial cells elicits the same type of
mediator response as does involvement of either
endothelial or mesangial cells. A recent study has
shown that PAF excretion is increased in
proportion to the degree of proteinuria in
membranous nephropathy in man.
52 Since it is well
established that PAF excretion is increased in lupus
nephritis in mice,
53 which is a proliferative cellular
nephritis this again emphasizes that general
statements can appertain.
Therapy of glornerulonephritis with
anti-inflammatory drugs
Owing to its ability to induce lipocortin,
54 cortisone
is our most powerful anti-inflammatory and
anti-allergic drug. It stops formation of the
eicosanoids and ofPAF and the release of cytokines
like IL-1 and TNFo. Yet effective usage is often
accompanied by serious side-effects. Indeed, corti-
costeroids are only now used with specific intent in
the nephritis of SLE (systemic lupus erythematosus)
in which various lymphocyte driven auto-immune
mechanisms are involved. Lymphocytes are easily
suppressed by cortisone. In other forms of
proliferative nephritis steroids are of little benefit.
The NSAIDs have been used to reduce
proteinuria in nephrotic syndrome. Yet there is
always the risk of allergic reaction and thus
superimposed interstitial nephritis and acute renal
failure. Hence currently the ACE inhibitors
55 are
more likely to be used for reduction of proteinuria.
The glomerular effects of angiotensin II are actually
mediated through the thromboxanes.
56
There is now great interest in the use of
thromboxane synthetase and thromboxane receptor
antagonists, for reasons that have been discussed.
Increased thromboxane formation has been demon-
strated in all human glomerulopathies e.g. in
minimal change nephrotic syndrome, in the various
proliferative nephritides and in diabetic nephro-
pathy. In animal experiments thromboxane ant-
agonism is successful in controlling hypertension,
proteinuria and declining renal function.41-44’57-59
The time for clinical trials has come, albeit the
remark could apply also to PAF and leukotriene
antagonists.
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